486 related articles for article (PubMed ID: 25953441)
1. Widespread renal polycystosis induced by crizotinib.
Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
[TBL] [Abstract][Full Text] [Related]
2. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
3. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
[No Abstract] [Full Text] [Related]
4. Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report.
Madabhavi I; Patel A; Anand A; Panchal H; Parikh S
Clin Respir J; 2018 Feb; 12(2):806-810. PubMed ID: 27606884
[TBL] [Abstract][Full Text] [Related]
5. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
6. [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
Toffart AC; Sakhri L; Moro-Sibilot D
Rev Pneumol Clin; 2013 Apr; 69(2):111-6. PubMed ID: 23561899
[TBL] [Abstract][Full Text] [Related]
7. The renal effects of ALK inhibitors.
Izzedine H; El-Fekih RK; Perazella MA
Invest New Drugs; 2016 Oct; 34(5):643-9. PubMed ID: 27468827
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
[TBL] [Abstract][Full Text] [Related]
9. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Efficacy of Crizotinib in Advanced ALK Positive
Non-small Cell Lung Cancer].
Zhao J; Zhang K; Zhang L; Wang H
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
[TBL] [Abstract][Full Text] [Related]
11. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
12. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
13. [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with bone marrow metastasis: case report and literature review].
Li X; Liu X; Gao F; Yin X
Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):85-8. PubMed ID: 25676401
[TBL] [Abstract][Full Text] [Related]
14. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma.
Sato Y; Fujimoto D; Shibata Y; Seo R; Suginoshita Y; Imai Y; Tomii K
Jpn J Clin Oncol; 2014 Sep; 44(9):872-5. PubMed ID: 24966207
[TBL] [Abstract][Full Text] [Related]
15. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
16. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
17. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
19. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]